Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David Miles(Guy's Hospital), Giulia Bianchi, David Cameron(Corewell Health), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xingchen Yan(Chinese Academy of Medical Sciences & Peking Union Medical College), S. Zhang, Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Q. Zhang, Clara Natoli(Kliniken Essen-Mitte), Filippo Montemurro(Roche (Switzerland)), Shilpen Patel, Alberto Zambelli, Valentina Guarneri(Istituto Oncologico Veneto), Joyce O’Shaughnessy(Baylor University Medical Center), Lorenzo Livi(European Society for Sexual Medicine), Francesco Ferraù(Université Paris-Sud), Marco Colleoni(European Institute of Oncology), Sipahee Lal Patel(Patient-Centered Outcomes Research Institute), Mattea Reinisch(University of Mannheim), James Chih‐Hsin Yang(National Taiwan University Hospital), Min Yan(Zhengzhou University), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Giuseppe Tonini(Campus Bio Medico University Hospital), Manika Kaul, Andrew Wardley(UK Research and Innovation), Semiglazov Vf(Institute of Oncology NN Petrov), Monika Patre(Roche (Switzerland)), Joseph Gligorov(Sorbonne Université), Kunwei Shen(Shanghai Jiao Tong University), Tao Sun(Liaoning Cancer Hospital & Institute), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Yongmei Yin(Nanjing Medical University), Andreas Schneeweiß(German Cancer Research Center), Diego Kaen(National University of La Rioja), Zhimin Shao(Goethe University Frankfurt), Zhongsheng Tong(Institute of Oncology NN Petrov), Xiangyu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiang Liu(Sun Yat-sen University), Cuizhi Geng(Hebei Medical University), Armando Santoro(IRCCS Humanitas Research Hospital), Carlos H. Barrios(Eastern Cooperative Oncology Group), L. Morales(Roche (Switzerland)), Livia Andrade(Santa Casa de Misericórdia de Marília), J Feng(Texas Oncology), Teresa Barata(Roche (Switzerland)), Fabrice André(Inserm), Yan Wang(National Institute of Biological Sciences, Beijing), Lorenzo Gianni
Cited by 724
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k